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ABSTRACT
Primary Purpose. The staging of regional nodes by
means of sentinel node detection has been shown to accu-
rately detect subclinical nodal metastases from cutaneous
melanoma. On the other hand, the oncological applications
of 18F-fluoro-2-deoxy-D-glucose positron emission tomog-
raphy (18FDG PET) are, nowadays, firmly established.
However, the sensitivity of such metabolic imaging for stag-
ing the regional nodes in primary melanoma remains debat-
able. We prospectively assessed the actual value of PET for
detecting sentinel node metastases in 21 consecutive patients
presenting with early-stage melanoma.
Materials and Methods. Twenty-one melanoma patients
scheduled for lymphatic mapping and sentinel lym-
phadenectomy underwent fully corrected whole-body PET
using 18FDG. In all cases, the disease was initially classified
as either stage I or II, from the latest version of the
American Joint Committee on Cancer staging system. The
sentinel node detection was systematically performed
within the week following the PET scan. Serial sections of
the sentinel nodes were analyzed by both conventional
pathology and immunohistochemical staining. Metastatic
sentinel nodes were also assessed for the size of tumor
deposits and the degree of nodal involvement (focal, partial,
or massive). The median follow-up time was 12 months.
Results. Six of the 21 patients (28.5%) had an involved
sentinel node. PET was positive in only one case with a
sentinel node >1 cm. In the five other cases, the sentinel
nodes missed by PET were <1 cm with focal and/or par-
tial involvements. One patient, free of regional nodal
metastases in both sentinel node detection and PET imag-
ing, had, however, a same-basin recurrence 3 months
later. In another case, PET had one false positive result.
Overall, the sentinel detection of subclinical nodal metas-
tases had a sensitivity of 86%. PET detected only 14% of
sentinel node metastases.
Conclusions. Sentinel node detection remains the pro-
cedure of choice for detecting subclinical lymph node
involvement from primary cutaneous melanoma. Owing
to its limited spatial resolution, PET appears insufficiently
sensitive to identify microscopic nodal metastases. As a
practical consequence, metabolic imaging is not recom-
mended as a first-line imaging strategy for staging regional
lymph nodes in patients with stage I or II melanoma. 
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INTRODUCTION
Malignant melanoma of the skin remains a critical public
health problem worldwide despite earlier diagnosis due to
screening and public education [1]. As melanoma cells pri-
marily spread through the lymphatic way, the N classification
of such lymphophilic cancer is a key step for treatment
planning and patient prognosis [2, 3].
According to the sentinel node theory, the disease pro-
gresses in an orderly fashion, and thus, affects the regional
nodes draining the primary tumor before disseminating to
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distant sites [4, 5]. Subsequently, the lymphatic mapping
followed by sentinel lymphadenectomy (LM/SL) has
become a valuable tool for detecting subclinical lymph node
metastases from melanoma [6-8]. Though even the thera-
peutic benefit of complete selective lymph node dissection
(CSLND) has not yet been proven, the clinical usefulness
of LM/SL in terms of staging accuracy and prognostic 
significance is widely recognized nowadays [7, 9, 10].
On the other hand, the utility of a sophisticated metabolic
imaging technology, such as positron emission tomography
(PET) using 18F-fluoro-2-deoxy-D-glucose (18FDG) for stag-
ing various malignancies, is firmly established. Many pub-
lished data report the capability of 18FDG PET in detecting
lymph node involvement missed by morphological imaging
procedures. Indeed, 18FDG PET has been shown to localize
metastatic deposits in normal-sized nodes [11-14]. Nonethe-
less, in pretreatment nodal staging of malignant melanoma,
the actual value of PET imaging is debatable. While initial
reports emphasized the high sensitivity of PET for detecting
impalpable metastatic nodes [15-19], more recent studies
underlined its low efficiency for diagnosing microscopic
nodal involvement [20-24]. For this purpose, we prospec-
tively evaluated the contribution of metabolic imaging for
detecting sentinel node metastases in 21 consecutive
patients presenting with early-stage primary melanoma,
which underwent both 18FDG PET imaging and LM/SL.
MATERIALS AND METHODS
Patient Population
Twenty-one consecutive melanoma patients (10 men,
11 women, mean age = 58 ± 11 years, Breslow’s thickness
= 1.89 mm) scheduled for a LM/SL underwent 18FDG PET
imaging in pretreatment staging. All patients included into
this institutional protocol were classified at stage I or II
cutaneous melanoma (T1-4 N0 M0) according to the latest
version of the American Joint Committee on Cancer
(AJCC) staging system [25]. The patients with histologi-
cally unproven primary melanoma or those with confirmed
but more advanced disease (AJCC stages III or IV), as well
as subjects previously treated for malignant melanoma or
other malignancies were systematically excluded from the
study group. Additionally, in our staging protocol, only the
patients who underwent LM/SL within the week following
the metabolic imaging were taken into account. The LM/SL
technique included, in a 1-day protocol, a preoperative lym-
phoscintigraphy followed by an intraoperative lymphatic
mapping using gamma probe guidance. Each patient was
individually followed with a median follow-up time of 12
months. Post-therapy surveillance included complete phys-
ical examination at the control visits and oriented imaging
procedures, such as computed tomography or PET, when
clinically indicated. All cases were managed by a multidisci-
plinary melanoma group study including a surgeon, a derma-
tologist, a nuclear physician, a pathologist, and an oncologist.
Patient characteristics are detailed in Table 1.
PET Imaging Procedure
All patients underwent fully corrected whole-body PET
imaging using either a PENN PET 240H scanner (UGM;
Philadelphia, PA), in 13 cases, or a C-PET scanner (Adac,
Philips Medical Systems; Milpitas, CA) in eight patients.
The spatial resolution of these scanners in clinical practice
approaches 1 cm. Patients fasted at least 4 hours before
injection time to reduce serum glucose and insulin levels to
near basal concentrations. Intravenous injection of diuretics
(furosemide, 10 mg) was performed to avoid bladder and
ureter artifacts. In addition, the patients received 10 mg of
diazepam orally about 1 hour prior to starting the study in
order to provide muscle relaxation. Patients were kept at
rest and were asked to void just before starting the acquisi-
tion. PET scans were performed 60 to 90 minutes after i.v.
injection of 259 to 333 MBq of 18FDG. Scanning started at
the inguinal region and proceeded to the neck. Optional
views were focused over the neck, the groin, or the
popliteal fossea in order to verify all physiological nodal
stations potentially draining the primary tumor. In all cases,
a whole-body segmented attenuation correction was per-
formed post-injection using singles transmission scans with
a 137Cesium external point source. The total scanning time
was, on average, 60 minutes. The data were reconstructed by
using an iterative method based on an ordered subset-expec-
tation maximization algorithm. UGM software was used for
data acquisition and processing. Finally, the images were
displayed on transversal, coronal, and sagittal slices and
were visually interpreted in routine clinical fashion.
LM/SL Procedure
Preoperative Lymphoscintigraphy
A mean activity of 37 MBq (1 mCi) of 99mTc-ultrafiltered
sulfur-colloid (Lymphoscint®; Nycomed Amersham Sorin®;
Milan, Italy; mean size = 50 nm) divided into four insulin
syringes (23-gauge) was injected intradermally (0.1 to 0.15 cc
per syringe) in two to four points around the primary site.
Massage and compression of the sites of injection for 1 to 2
minutes were applied to stimulate the lymphatic flow.
Dynamic sequences followed by static spot views over the
lymphatic basins were performed using a DSX rectangular
gamma camera (Sopha Medical; GE Medical Systems
Benelux, Diegem, Belgium). A 57Cobalt flood was also placed
under the gamma camera performing a virtual transmission in
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order to define the body contours, and thus, to localize more
accurately the site of the sentinel lymph nodes (SLNs). For
the axillary areas, optional views were acquired mimicking
the surgical position of the patients. According to the standard
definition, the first lymph node identified on the initial scans
and confirmed on at least two static images was considered as
the SLN [8]. The skin covering the SLN was tattooed to guide
the surgical excision.
Intraoperative Gamma Probe Guidance
Three to four hours after the preoperative lymphoscintig-
raphy, the patients were referred to the operating room. Intra-
operative lymphatic mapping was performed by using a
hand-held gamma probe (Navigator® using a CdTe detector;
Autosuture®, Tyco Healthcare; Mechelen, Belgium). Radio-
activity (in counts/sec) of the SLNs and the adjacent non-
SLNs was measured in vivo and verified ex vivo after
removal. A signal to background ratio higher than 2 to 3 in
vivo and higher than 10 ex vivo was considered significant.
After excision of the SLNs, the lymphatic basin was
rechecked for radioactivity. The use of blue dye was left at the
discretion of the surgeon. In all cases, the LM/SL procedure
was performed by the same surgical team.
Histologic Analysis of the SLNs
Serial sections of the SLNs were examined by the same
pathologist using, in all cases, both conventional pathology
(hematoxylin and eosin) and immunohistochemical stains
with antibodies to S-100 protein, HMB-45, and NKIC3 anti-
gens. In cases of involved SLNs, the tumor deposits were
microscopically measured and the lymph node involvement
was described as massive, partial, or focal following the
degree of lymph node invasion.
Statistical Analysis
The results of 18FDG PET and LM/SL were expressed in
terms of sensitivity, specificity, diagnostic accuracy, and posi-
tive and negative predictive values, respectively. Estimates are
presented with a 95% confidence interval (95% CI). Any
hypermetabolic focus detected by PET in the lymphatic basin
draining the primary tumor was considered as true positive
when the result matched with an SLN histologically involved.
Otherwise, all hypermetabolic foci not confirmed by the his-
tology or corresponding to inflammatory nodes were inter-
preted as false positive results. A negative PET scan matching
with an SLN histologically free of tumor was considered as
true negative. Conversely, the result of PET was considered as
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Table 1. Patient characteristics
Patient Age Gender Primary Breslow’s Clark’s level AJCC
n (year) tumor sites depth (mm) Stage
1 52 M Head and neck 2.4 IV II
2 62 M Head and neck 3.6 IV II
3 46 F Lower extremity 0.6 II Ia 
4 49 F Trunk 2.8 IV II 
5 49 M Lower extremity 1.7 IV Ib 
6 39 F Trunk 0.56 III Ia 
7 65 F Lower extremity 4.25 V II 
8 58 F Trunk 1.33 IV Ib 
9 66 M Trunk 1.4 IV Ib 
10 76 M Upper extremity 3.85 IV II 
11 44 F Upper extremity 0.5 I Ia 
12 50 F Trunk 1.3 IV II 
13 78 M Upper extremity 0.7 III Ia 
14 48 F Upper extremity 2.1 IV II 
15 50 M Upper extremity 1.18 IV Ib 
16 74 M Trunk 1.1 IV Ib 
17 77 F Upper extremity 1.6 IV Ib 
18 73 F Head and neck 4.56 V II 
19 48 M Lower extremity 2.35 IV II 
20 63 F Lower extremity 0.73 IV Ia 
21 59 M Trunk 1.4 IV Ib
Abbreviation: AJCC = American Joint Committee on Cancer (Last version 2001).
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falsely negative when the SLN detected by LM/SL was histo-
logically involved. The same-basin recurrences were also con-
sidered as false negative results of PET and/or LM/SL when the
initial interpretation did not conclude to a nodal involvement.
RESULTS
In the present series, 6 of the 21 melanoma patients
(28.5%) had an involved SLN, which was easily localized in
both preoperative and intraoperative detection. PET was posi-
tive in only one patient, who had a metastatic SLN measuring
1.8 cm with massive involvement and capsular infiltration (Fig.
1). This patient was clinically classified at AJCC stage II dis-
ease at the time of the PET scan and had progressed to AJCC
stage IV melanoma after the diagnosis of microscopic lung
metastases on a thoracic computed tomography. In the five
other cases, the positive SLNs missed by the metabolic imag-
ing were <1 cm, and most often harbored microscopic and
focal tumor deposits (Fig. 2). Two of these (2/5) were only
detected by using immunohistochemical stains. Another
patient with AJCC stage I disease had a confirmed same-basin
recurrence 3 months after intervention, while both LM/SL and
PET were initially negative. In addition, PET had one false
positive result and 13 true negatives (SLNs free of tumor and
no subsequent recurrence) with a median follow-up of 12
months. The patients having a positive SLN underwent
CSLND followed by high-dose systemic adjuvant interferon
α-2B according to the scheme of Kirkwood et al. [26].
Otherwise, the patients with negative SLNs had no subsequent
treatments and were clinically followed up at the control visits.
Overall, in pretreatment staging of subclinical melanoma
nodal metastases, LM/SL had an 86% sensitivity, a 100%
specificity, a 95% diagnostic accuracy, a 100% positive pre-
dictive value, and a 93% negative predictive value. For detect-
ing SLN metastases, PET had a 14% sensitivity, a 93%
specificity, a 67% diagnostic accuracy, a 50% positive predic-
tive value, and a 68% negative predictive value. The perfor-
mances of each procedure with their 95% confidence intervals
are summarized in Table 2.
DISCUSSION
In melanoma patients presenting with AJCC stage I or
II disease, the histological status of the regional lymph
nodes is the most important prognostic factor [27]. This
explains why it is crucial to achieve an accurate nodal stag-
ing in patients at risk of metastases. Such a need is even more
warranted by the survival benefit obtained in patients with
nodal involvement treated by high-dose systemic adjuvant
interferon α-2B [26].
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Figure 1. A case of malignant melanoma of the left foot (Breslow’s depth = 4.5 mm). 18FDG PET imaging (A) accurately detected an involved
sentinel node harvested at the left groin (B). Histology revealed that the sentinel node measured 1.8 cm and had massive tumor involvement with
capsular infiltration (C). 18FDG PET = 18F-fluoro-2-deoxy-D-glucose positron emission tomography; SLN = sentinel lymph nodes.
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Introduction of LM/SL in malignant melanoma was a
substantial advance for the detection of subclinical nodal
metastases. The technique is, nowadays, standardized and
allows for the selection of a subset of patients presenting with
clinically unsuspected involvement of their sentinel nodes for
complete lymphadenectomy and systemic adjuvant treat-
ments. Moreover, the procedure is useful to avoid the cost and
morbidity of unnecessary elective lymph node dissections in
the wide majority of the patients with an SLN free of tumor
[6-10]. Owing to the determinant data provided by LM/SL in
the management of patients with stage I and II melanoma, the
results of this procedure recently have been incorporated into
the last version of the revised AJCC staging system [25].
On the other hand, the value of 18FDG PET for staging
various malignancies is firmly established [11-14]. In pre-
treatment nodal staging of malignant melanoma, however, the
role of metabolic imaging is less evident. Despite the opti-
mistic conclusions of initial reports, more recent prospective
and retrospective studies are less enthusiastic about the actual
performance of PET for detecting occult lymph node metas-
tases. For instance, in 13 patients, Gritters et al. reported the
detection of melanoma metastases in 100% of the lymph node
basins [15]. Similarly, in 11 melanoma patients submitted to
complete lymphadenectomy of 14 nonpalpable lymph node
basins, Wagner et al. reported a sensitivity and a specificity of
100% for the detection of nodal metastases by means of
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Figure 2. A case of malignant melanoma of the back (Breslow’s depth = 1.33 mm). 18FDG PET imaging was negative (A). The sentinel node
located at the right axilla was involved (B). Histology showed focal tumor deposits measuring 0.6 cm (C). 18FDG PET = 18F-fluoro-2-deoxy-D-
glucose positron emission tomography; SLN = sentinel lymph nodes.
Table 2. Overall results
PET LM/SL
Sensitivity (95% CI) 14% (0-28) 86% (72-100)
Specificity (95% CI) 93% (83-103) 100% (100-100)
Diagnostic accuracy (95% CI) 67% (47-87) 95% (86-104)
Positive predictive value (95% CI) 50% (29-71) 100% (100-100)
Negative predictive value (95% CI) 68% (49-88) 93% (83-103)
Abbreviations: PET = positron emission tomography; LM/SL = lymphatic mapping/sentinel lymphadenectomy; CI = confidence interval.
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18FDG PET [18]. Several other studies also confirmed the per-
formance of 18FDG PET for the detection of occult or residual
lymph node metastases [12, 14, 16, 17, 19]. Nonetheless, only
a few studies recently addressed the value of metabolic imag-
ing for staging subclinical nodal metastases detected by the
LM/SL procedure. In a prospective study of 70 patients pre-
senting with AJCC stage I, II, or III cutaneous melanoma,
Wagner et al. first compared PET imaging of regional lymph
node basins with sentinel node biopsy results (SNB). They
concluded that PET had a sensitivity of 16.7% and a speci-
ficity of 95.8% versus 94.4% and 100%, respectively, for
SNB [20]. Similar observations were reported by Acland et al.
in a prospective study of 50 patients with primary melanoma
>1 cm thick or lymphatic invasion [21]. Of the 14 patients
with positive SLNs, PET detected none of them. More
recently, Kokoska et al. prospectively evaluated the value of
PET and lymphoscintigraphy in the management of 18 head
and neck melanoma patients [24]. Sentinel nodes were found
in 94.4% of the patients, in which 5/18 (27.8%) had metas-
tases. PET detected nodal metastases in three patients
(16.7%), and only one of them had a positive SLN. In another
study, Acland et al. retrospectively showed that the sensitivity
of PET was correlated with the AJCC stage of melanoma dis-
ease [22]. They found a high sensitivity of 93% for stage III,
but the value dramatically fell to 50% and 33% for stages I
and II, respectively. They concluded that PET is a valuable
procedure for staging the patients with known regional spread
but is suboptimal in stage I or stage II disease. Similarly, in a
prospective study of 95 patients, Tyler et al. confirmed the
clinical utility of 18FDG PET imaging in melanoma patients
with AJCC stage III disease [28].
To determine the factors that may influence the sensitivity
of the metabolic imaging for detecting melanoma nodal metas-
tases, Crippa et al. analyzed the value of PET in terms of
lymph node size [29]. In a retrospective study of 36 patients
presenting with confirmed lymph node metastases from
melanoma, the authors showed that PET had only a 23% sen-
sitivity for lymph node metastases ≤5 mm, while the sensitiv-
ity increased to 83% and 100%, respectively, for metastases
that were 6-10 mm and ≥10 mm. More recently, Wagner et al.
retrospectively studied the tumor volume threshold for suc-
cessful PET imaging of melanoma nodal metastases in 45
patients with 49 pathologically positive regional nodal basins
[23]. The sensitivity of PET for detection of all tumor volumes
was 49%. The observed 90% sensitivity threshold of nodal
metastases was ≥78 mm3. PET sensitivity fell to 14% for
detection of tumor volumes <78 mm3. Indeed, the PET sensi-
tivity differed by prescan AJCC stage: 0% (stage I), 24%
(stage II), 81% (stage III), and 100% (stage IV).
Although these prospective and retrospective trials
assessed the sensitivity of metabolic imaging for detecting
sentinel node metastases on large patient populations, they
had technical biases regarding their PET protocol. For
instance, a correction of attenuation and an iterative recon-
struction, two key parameters affecting the quality of the
images, and thus, the sensitivity of the technique, were
inconsistently or never performed [30-32]. Despite the rel-
atively limited sample size of our study group, the results
were enhanced by fully corrected whole-body PET imag-
ing, blinded PET interpretations, use of single PET exam-
iner, and iterative data reconstruction in all cases. Indeed,
the prospective nature of the study with a median follow-up
time of 12 months, as well as the strict adherence to LM/SL
protocol performed by the same surgical team, detailed his-
tological analyses of SLN specimens by the same patholo-
gist, and multidisciplinary review of all clinical cases were
other important points strengthening the robustness of our
conclusions. Overall, our data demonstrated the inability of
PET to visualize infracentimetric sentinel node metastases
in patients with early-stage melanoma. Although statisti-
cally limited, our results are similar to those published by
Wagner and Acland from larger series (≥50 patients) [20,
21]. Both authors concluded on the inability of PET to
detect microscopic metastases located in sentinel nodes.
Also, our results provide additional arguments regarding
the comparison of PET with sentinel node biopsy using an
optimal methodology, and thus, avoiding the technical
biases characterizing the available data from the literature,
thereby inciting further studies with larger series to defi-
nitely confirm our conclusions. The limited spatial resolu-
tion of commercially available PET devices is certainly the
main reason explaining the low sensitivity of PET for
detecting microscopic lymph node metastases. Another
important issue is the detector materials characterizing the
PET scanners. In all published studies, the imaging was per-
formed using Siemens ECAT line devices with bismuth ger-
manate (BGO) detectors. We used two types of the same
PET scanner (PENN PET and C-PET). Both had 6 thallium-
doped sodium iodine detectors (NaI [Tl]), but the curved
detectors and larger axial field of view characterizing the C-
PET model contribute to improve its count-rate capability
and spatial resolution in comparison with the PENN PET
[33, 34]. All these devices, regardless of their constructors,
are representative of mid-end PET scanners commonly used
in the field of oncology. Their theoretical spatial resolution
is about 6 mm. In clinical practice, however, their resolution
is around 1 cm and certainly more for uncorrected images.
The recent introduction of lutetium oxyorthosilicate (LSO)
and gadolinium oxyorthosilicate (GSO) detectors in high-
end PET scanners could improve the detection efficiency
[13]. Both LSO and GSO are faster than either BGO or NaI
[Tl], and both scintillating materials also have a higher
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effective Z and density than NaI [Tl]. Future improvements
in the correction of scatter fraction, as well as the imple-
mentation of more effective iterative methods for data
reconstruction and the use of more powerful processing sys-
tems could also substantially increase the sensitivity and the
resolution of the PET scanners [13, 35-39]. Nonetheless, we
believe that the spatial resolution of these new PET systems
would still be insufficient to detect 1 or 2 melanoma cells in
normal-sized nodes. As demonstrated by the present study,
most of the involved sentinel nodes harbored microscopic
and focal tumor deposits, requiring, in two patients, sophis-
ticated immunostaining techniques. In another case, the
same-basin recurrence also showed the current limits of
LM/SL and indicated the need for still more sensitive tools.
For this purpose, the use of reverse transcriptase-polymerase
chain reaction assay could be an efficient adjunct to detect
the false negatives of both LM/SL and PET [40, 41].
Controlled trials using high-end PET with LSO or GSO
detectors are, however, necessary to assess their actual per-
formances in detecting infracentimetric nodal metastases
from melanoma. Also, following evidence-based medicine
methods, our results, and those reported by others, support
the idea that an optimal regional nodal staging of patients
with early-stage melanoma would be better achieved using
lymphatic mapping and sentinel lymphadenectomy rather
than 18FDG PET imaging, thereby avoiding time-consuming
and expensive unnecessary imaging procedures. Metabolic
imaging remains, however, a valuable tool for whole-body
staging of more advanced disease.
CONCLUSIONS
The LM/SL technique remains the procedure of choice
for evaluating the histologic status of the lymphatic basins
in patients with early-stage cutaneous melanoma. PET
imaging appears insufficiently sensitive for localizing
microscopic sentinel node metastases given its current spa-
tial resolution. Based on our results and data from literature,
we do not recommend 18FDG PET as a first-line imaging
strategy for staging patients with AJCC stage I or II primary
disease. Further prospective and multicentric trials, includ-
ing larger series of melanoma patients and using high-end
PET scanners with optimal methodology, are needed to
confirm our conclusions.
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